Bioheart, Inc. Announces Resignation of Howard J. Leonhardt as Chief Technology Officer, Chairman of the Scientific Advisory Board, and as Member of the Board of Directors
February 09, 2013 at 02:33 am IST
Share
Bioheart, Inc. announced that Howard J. Leonhardt resigned as Chief Technology Officer, Chairman of the Scientific
Advisory Board, and as a member of the Board of Directors to pursue other business matters.
U.S. Stem Cell, Inc. is a biotechnology company. The Company is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. MyoCell SDF-1 is similar to MyoCell except that the myoblast cells to be injected for use in MyoCell SDF-1 will be modified prior to injection by an adenovirus vector or non-viral vector. Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. It is also investigating the use of adipose cells in a variety of clinical applications.
Bioheart, Inc. Announces Resignation of Howard J. Leonhardt as Chief Technology Officer, Chairman of the Scientific Advisory Board, and as Member of the Board of Directors
U.S. STEM CELL, INC. 
